Skip to main content

Table 2 Quality analysis of the pcDNA-CCOL2A1 vaccine via different purification procedures

From: An innovative lab-scale production for a novel therapeutic DNA vaccine candidate against rheumatoid arthritis

Impurity

Analytical method

PEG/MgCl2

IEC

Commercial kit

Acceptance criteria

Appearance

Visual inspection

Clear, colourless

Clear, colourless

A260/A280

UV spectrophotometer

1.98 ± 0.02

2.00 ± 0

2.10 ± 0.10

 ≥ 1.75a

1.75–1.85b

Endotoxin (EU/mg)

LAL assay

4.25 ± 0.40

5.31 ± 0.53

4.66 ± 0.48

 ≤ 10 EU/mga, b

 ≤ 40 EU/mg c

E. coli protein (μg/mg)

ELISA

Undetectable

 ≤ 1 μg/mga

 ≤ 10 μg/mg b

 < 1% c

E. coli gDNA (μg/mg)

Q-PCR

2.09 ± 0.18**

3.45 ± 0.57*

7.49 ± 0.07

 ≤ 2 μg /mga

 ≤ 10 μg/mg b

 < 1%c

E. coli RNA (%)

AGE

Not visible

10.11%

Not visible

Not visiblea, b

 < 1%c

Supercoiled (%)

HPLC/AGE

94.98%

71.24%

93.67%

 ≥ 90%a, b

 ≥ 80%c

  1. Data are expressed as the mean ± standard deviation (SD) of three independent batch experiments. *P < 0.05, ** P < 0.001
  2. Abbreviations: AGE Agarose gel electrophoresis, ELISA Enzyme-linked immunosorbent assay, EU/mg Endotoxin units per milligram, gDNA genomic DNA, HPLC High-performance liquid chromatography, LAL assay Limulus amoebocyte lysate assay, Q-PCR Quantitative polymerase chain reaction
  3. aNMPA guidelines
  4. bEAEM guidelines
  5. cUS FDA guidelines